Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

NuVasive’s MaXcess Retractor Published Study in the Journal of Neurosurgery: Spine Further Validates Prone, Single-Position Lateral Interbody Fusion

October 5, 2020

Results of the study, “Single-position prone lateral approach: cadaveric feasibility study and early clinical experience,” in The Journal of Neurosurgery: Spine, which features NuVasive’s MaXcess retractor and further validates prone, single-position lateral interbody fusion was announced today.

“As the global leader in lateral spine surgery, NuVasive remains committed to developing comprehensive, procedural solutions that provide a truly patient-specific and optimized surgical outcome,” said Massimo Calafiore, senior vice president and general manager of NuVasive’s spine business unit. “This study adds to the growing body of evidence validating the NuVasive MaXcess retractor’s ability to perform lateral surgery in a variety of approaches, including prone position. Further, it highlights the utility of this approach, as well as its limitations, as not all patients were able to be treated in the prone position, and underscores the value of NuVasive’s X360 system—which offers a complete solution for our surgeon partners.”

The paper details a two-part study of prone, single-position lateral interbody fusion: the first provides cadaveric feasibility data to the lateral approach with the patient in the prone position, and the second explores the initial clinical experience of prone, single-position lumbar interbody fusion at two centers. A total of eight levels were treated in the cadaveric specimens, without any visceral, vascular or endplate violations noted. In the clinical series, 11 of 12 patients were able to be treated with prone, single-position lateral interbody fusion successfully, with no endplate violations or resultant subsidence. The one patient who could not have a successful prone, single-position lateral interbody fusion was converted to a single-position lateral interbody fusion procedure without incident. This study builds upon previous literature validating the prone position using NuVasive’s MaXcess retractor, a key tool in the Company’s X360™ system, and represents the largest clinical series published to date describing outcomes of prone position for a lateral approach. The authors concluded that prone positioning, in select patients, is a safe and reproducible alternative that can increase efficiency and decrease operative time.

“Prone positioning for a lateral approach presents an exciting opportunity for streamlining surgical access to the lumbar spine and facilitating a more efficient surgical solution with potential clinical and economic advantages for certain patients,” said Juan Uribe, MD, chief of the division of spinal disorders at Barrow Neurological Institute in Arizona. “As a long time XLIF user, I am grateful for NuVasive‘s leadership in developing single-position procedural technologies that support a variety of positions and span the entire patient care continuum.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy